Try
BioNTech SE
BNTXUnited States
10 filed reports · 292 financial concepts · 2 earnings calls · 13 media appearances
Filed reports
10 reports · Dec 2019 to Dec 2025Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 20 commentary passages.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Annual · 20-FSEC EDGAR | 7 | 187 | Dec 2019 to Dec 2025 |
| Annual · 20-F/ASEC EDGAR | 3 | 889 | Dec 2021 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2025 | 20-F/A | Dec 31, 2025 | Jul 30, 2026 | 1 | Open |
| FY2025 | 20-F/A | Dec 31, 2025 | Jul 30, 2026 | 848 | Open |
| FY2025 | 20-F | Dec 31, 2025 | Mar 10, 2026 | 1 | Open |
| FY2025 | 20-F | Dec 31, 2025 | Mar 10, 2026 | 4 | Open |
| FY2024 | 20-F | Dec 31, 2024 | Mar 10, 2025 | 26 | Open |
| FY2023 | 20-F | Dec 31, 2023 | Mar 20, 2024 | 33 | Open |
| FY2022 | 20-F | Dec 31, 2022 | Mar 27, 2023 | 21 | Open |
| FY2021 | 20-F/A | Dec 31, 2021 | Oct 26, 2022 | 40 | Open |
| FY2020 | 20-F | Dec 31, 2020 | Mar 30, 2021 | 29 | Open |
| FY2019 | 20-F | Dec 31, 2019 | Mar 31, 2020 | 73 | Open |
Financial data
292 concepts · 1,076 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial280 concepts · 947 facts · Dec 2018 to Mar 2026
- Cash and cash equivalents10 · Dec 2023 to Dec 2025
- Revenue9 · Dec 2018 to Dec 2025
- Lease liabilities, loans and borrowings8 · Dec 2024 to Dec 2025
- Other8 · Dec 2024 to Dec 2025
- Common Shares Outstanding7 · Mar 2020 to Mar 2026
- Contract assets6 · Dec 2023 to Dec 2025
- Contract liabilities6 · Dec 2023 to Dec 2025
- Cost of Revenue6 · Dec 2018 to Dec 2023
- Current contract assets (IFRS)6 · Dec 2023 to Dec 2025
- Current contract liabilities (IFRS)6 · Dec 2023 to Dec 2025
- Deferred tax liability asset6 · Dec 2023 to Dec 2025
- Equity6 · Dec 2023 to Dec 2025
- Financing Cash Flow6 · Dec 2018 to Dec 2023
- Income Tax Expense (Benefit)6 · Dec 2018 to Dec 2023
- Interest Expense6 · Dec 2018 to Dec 2023
- Inventory6 · Dec 2018 to Dec 2023
- Investing Cash Flow6 · Dec 2018 to Dec 2023
- Liabilities arising from financing activities6 · Dec 2023 to Dec 2025
- Net Income6 · Dec 2018 to Dec 2023
- Noncurrent contract assets (IFRS)6 · Dec 2023 to Dec 2025
- Noncurrent contract liabilities (IFRS)6 · Dec 2023 to Dec 2025
- Operating Cash Flow6 · Dec 2018 to Dec 2023
- Operating Income6 · Dec 2018 to Dec 2023
- Pretax Income6 · Dec 2018 to Dec 2023
Segment5 concepts · 47 facts · Dec 2018 to Dec 2019
- Revenue16 · Dec 2018 to Dec 2019
- R&D Expense12 · Dec 2018 to Dec 2019
- Gross Profit11 · Dec 2018 to Dec 2019
- Cost of Revenue5 · Dec 2018 to Dec 2019
- Operating Income3 · Dec 2018 to Dec 2019
Product4 concepts · 46 facts · Dec 2018 to Dec 2025
- Revenue30 · Dec 2018 to Dec 2025
- Percentage of entitys revenue9 · Dec 2023 to Dec 2025
- Cost of Revenue5 · Dec 2019 to Dec 2023
- Inventory2 · Dec 2022 to Dec 2023
Geography3 concepts · 36 facts · Dec 2020 to Dec 2025
- Revenue23 · Dec 2020 to Dec 2025
- Percentage of entitys revenue12 · Dec 2023 to Dec 2025
- United States1 · Dec 2025
Segments
129 factsFigures broken down by business line, region, product or another axis the company reports on.
Segments6 members · 47 facts
- Reportable segments11 · Dec 2018 to Dec 2019
- Product sales and external services business unit10 · Dec 2018 to Dec 2019
- Technology platform business unit8 · Dec 2018 to Dec 2019
- Manufacturing business unit7 · Dec 2018 to Dec 2019
- Clinical business unit6 · Dec 2018 to Dec 2019
- Business service business unit5 · Dec 2018 to Dec 2019
Product or service8 members · 37 facts
- Commercial9 · Dec 2019 to Dec 2023
- COVID19 Vaccine Revenues6 · Dec 2023 to Dec 2025
- Other Sales6 · Dec 2023 to Dec 2025
- Revenues From Out Licensing6 · Dec 2023 to Dec 2025
- Research and development5 · Dec 2019 to Dec 2023
- Omicron xbb.1.5 adapted monovalent covid19 vaccine3 · Dec 2022 to Dec 2023
- Covid19 vaccine revenues1 · Dec 2023
- Other sales1 · Dec 2023
Statement geographical8 members · 36 facts
- US7 · Dec 2023 to Dec 2025
- DE6 · Dec 2023 to Dec 2025
- IE6 · Dec 2023 to Dec 2025
- Rest Of The World6 · Dec 2023 to Dec 2025
- De4 · Dec 2020 to Dec 2023
- Us4 · Dec 2020 to Dec 2023
- Be2 · Dec 2020 to Dec 2021
- Rest of the world1 · Dec 2023
Products and services4 members · 9 facts
- Collaboration agreement3 · Dec 2020
- Other sales transactions3 · Dec 2018 to Dec 2020
- Collaboration and license agreements2 · Dec 2018 to Dec 2019
- Bill and hold transaction1 · Dec 2019
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Management discussion (MD&A) commentary44 claims from 2 reports · Dec 2024 to Dec 2025
- Risk-factor changes18 claims from 1 reports · Dec 2025
- Risk factors217 risks from 2 annual reports · 2024 to 2025
Earnings calls
2 calls · May 2026 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 4, 2026
- FY2026 Q1May 5, 2026
Executive media
13 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- Other appearances6 · Dec 2020 to Dec 2021
- TV interviews5 · Oct 2020 to May 2021
- Conference talks2 · Feb 2021 to Dec 2021
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.